How to Evaluate a Drug Development Pipeline

By Kevin Fernando · Sep 28, 2026 · 13 min read

Evaluate a drug pipeline by locating all programs in SEC filings and clinical trial registries, classifying them by development stage, applying historical success rates adjusted for trial design and competitive factors, estimating time to market and peak sales, sizing the addressable patient population, and combining these into a risk-adjusted valuation. This framework reveals which pipelines carry genuine commercial potential and which rely on speculative early-stage assets.

A drug development pipeline is a portfolio of programs at different stages of clinical and regulatory development. Investors and analysts often treat pipeline headlines as proxies for future value: "12 programs in Phase 2" sounds more impressive than "3 programs in Phase 3." But stage alone does not determine value. A Phase 2 program in a crowded market with weak trial design may never reach patients, while a Phase 3 program in an underserved indication with clean data may generate billions in annual sales.

Evaluating a pipeline requires extracting quantifiable data from public filings and clinical trial registries, applying historical success benchmarks, and adjusting those benchmarks for program-specific factors. The goal is to move from headline counts to a credible estimate of which programs will reach market, when, and at what scale. This guide teaches the framework and the data sources.

What you'll be able to do

After working through this guide, you will be able to locate all active programs in a company's pipeline, classify each by its position in the approval pathway, estimate the probability that each advances to the next stage, project when revenue will materialize, and calculate a risk-adjusted value for the entire portfolio. You will also recognize warning signs that pipeline quality is weaker than the headline stage distribution suggests. This requires familiarity with SEC filings and basic financial modeling, but not clinical expertise. You do not need to understand the biology; you need to understand the process and the data.

Map the pipeline by development stage

The first step is to locate and categorize every active program. A pipeline is only as valuable as the programs in it, and you cannot assess value without knowing what you have. Most companies disclose their pipeline in regulatory filings and on their websites, but the formats vary widely. You need to extract the data into a consistent framework.

Locate pipeline data in SEC filings and clinical trial registries

Start with the company's most recent 10-K or 10-Q filing. Search for "pipeline," "development," or "programs" to find the section where the company lists its active candidates. The company will usually provide the drug name, the indication (disease or condition it targets), and the current development stage. Write down each program and its stage.

Next, cross-check this list against ClinicalTrials.gov, a public registry maintained by the U.S. National Institutes of Health. Search for the company name and the drug name. ClinicalTrials.gov shows which trials are actively recruiting, which have completed, and what the trial design was. This step serves two purposes: it confirms the company's pipeline disclosure and it gives you trial-level detail that the company may not emphasize in its filing.

If the company is based outside the United States, also check the European Union Clinical Trials Register (EudraCT) and regional registries in other major markets. A program may be in Phase 2 in the United States but Phase 3 in Europe, and the timeline to market depends on which geography you are analyzing.

Classify each program by stage and indication

Create a spreadsheet with columns for drug name, indication, current stage, date entered current stage, and any accelerated designation (fast track, breakthrough therapy, priority review). The stages are preclinical, Phase 1, Phase 2, Phase 3, and regulatory review (NDA or BLA pending). Some companies use substages like "Phase 2a" or "Phase 2b," but for valuation purposes, treat these as Phase 2.

Indication matters because a single drug may be in development for multiple diseases. Ibrutinib, for example, is approved for chronic lymphocytic leukemia but is also in trials for other cancers and autoimmune conditions. Each indication is a separate program with its own timeline and market size. List them separately in your spreadsheet.

Once you have the full list, count how many programs sit in each stage. This distribution is your first signal of pipeline risk. A pipeline with 60% of programs in Phase 1 and only one in Phase 3 is very different from one balanced across stages, even if both have the same total program count.

Assess probability of success for each stage

Not every program will reach market. Historical data shows that most drugs fail. Your job is to estimate the probability that each program in the pipeline advances to the next stage and ultimately reaches approval. You will start with historical benchmarks and then adjust them for program-specific factors.

Apply historical success rates as a baseline

Historical success rates vary by stage. Phase 1 trials have the highest success rate because they are small, focused on safety, and do not require proof of efficacy. Approximately 63 to 70 percent of drugs successfully pass Phase 1 clinical trials. Phase 2 is where most drugs fail: only about 30 to 40 percent of drugs pass Phase 2 trials. Phase 3 is larger and more rigorous than Phase 2. Across all clinical phases, only about 10 percent of drugs that enter clinical trials eventually receive FDA approval.

To estimate the probability that a program reaches approval, multiply the success rates at each remaining stage. Suppose a drug is currently in Phase 2. Use 35 percent as the midpoint Phase 2 success rate. If Phase 3 success is roughly 50 percent (a reasonable estimate for programs that make it to Phase 3), and regulatory review success is roughly 90 percent, the cumulative probability is 0.35 times 0.50 times 0.90, or about 16 percent.

For context, the average likelihood of first approval rate across leading research-based pharmaceutical companies is 14.3 percent, broadly ranging from 8 to 23 percent. This suggests that a 16 percent estimate for a Phase 2 program is reasonable and in line with industry experience.

Adjust for program-specific factors

Baseline success rates are starting points, not destinations. Real programs differ in ways that move their odds up or down. The key adjustments are trial design, patient population, competitive context, and regulatory pathway.

Trial design matters because a well-designed Phase 2 trial with a clear primary endpoint and appropriate control arm is more likely to succeed and more likely to translate to Phase 3 success than a small, exploratory trial in a narrow patient population. Check ClinicalTrials.gov for the trial's design: Is it randomized? Does it compare the drug to a control or standard of care? How large is the patient population? A Phase 2 trial with 200 patients in a randomized, controlled design provides stronger evidence than a 50-patient open-label trial. Adjust your baseline success rate up for the former and down for the latter.

Patient population affects both trial success and commercial viability. A drug for a rare disease with a clear biomarker may have higher trial success rates because the patient population is homogeneous and the effect size is larger. Conversely, a drug for a common condition like hypertension may have lower trial success because the population is heterogeneous and the effect size is smaller. If the company is targeting a narrow, well-defined population, increase your success estimate. If it is targeting a broad population, decrease it.

Competitive context shapes both approval odds and commercial value. A drug entering a crowded market faces higher regulatory scrutiny because the FDA will compare it to existing options. A drug addressing an unmet need or a gap in treatment may face lower regulatory bar and higher commercial potential. Research the competitive landscape using PubMed, FDA approval databases, and company filings. If the drug is one of five Phase 3 programs in the same indication, reduce your success estimate. If it is the only program in a rare disease, increase it.

Regulatory pathways also matter. A drug with a Priority Review designation has an FDA goal of action within 6 months, compared to 10 months under standard review. A drug with breakthrough therapy or fast track designation signals that the FDA believes the drug addresses an unmet medical need. These designations do not guarantee approval, but they do suggest higher regulatory momentum. If a program carries an expedited designation, increase your success estimate by 5 to 10 percentage points.

Estimate timeline to market and peak sales

Timeline and sales are the other two drivers of pipeline value. A drug that reaches market in 2 years is worth far more than an identical drug that reaches market in 10 years, because revenue starts sooner and the company avoids years of development costs. Similarly, a drug with peak sales of $500 million annually is worth more than one with peak sales of $50 million, even if both have the same approval probability.

Timeline starts from today. Add the expected duration of each remaining phase. Preclinical research typically takes 3 to 6 years of laboratory work, animal studies, and toxicology testing before any drug is tested in the human body. Phase 1 typically takes 1 to 2 years. Phase 2 typically takes 2 to 3 years. Phase 3 typically takes 2 to 3 years. Clinical trial phases in total span roughly 6 to 7 years on average from first human dose to regulatory submission. After completing Phase 3 clinical trials, sponsors must compile comprehensive documentation for an NDA or BLA, which typically requires 6 to 12 months of intensive effort. Regulatory review takes approximately 1 year under standard FDA review, faster under priority or accelerated pathways. It takes an estimated 8.5 years on average for a drug to go from early laboratory discovery to approval for human use.

For a Phase 2 program, add 3 years for Phase 3, 1 year for NDA preparation, and 1 year for regulatory review. That is 5 years to approval from today. For a Phase 1 program, add 2 years for Phase 2, 3 years for Phase 3, 1 year for NDA, and 1 year for review. That is 7 years to approval.

Peak sales depend on market size and the drug's competitive position. Peak sales are typically reached 3 to 5 years after launch for specialty drugs and 5 to 8 years for primary care drugs. To estimate peak sales, first estimate the addressable market. Addressable market size is estimated by multiplying country population by prevalence or incidence of disease, then by diagnosis rate and treatment rate. For a rare disease with 10,000 patients in the United States and an average annual drug cost of $100,000, peak sales might be $1 billion. For a common disease with 5 million patients and an average annual drug cost of $5,000, peak sales might be $25 billion. Adjust downward if the drug faces competition and upward if it is the only option in its indication.

Evaluate competitive positioning and market size

A drug's value depends not just on whether it works, but on whether it works better than or differently from what already exists. A Phase 3 program in a crowded market may have lower commercial value than a Phase 2 program in an unmet need, even if the Phase 3 program has higher approval odds.

Start by identifying all approved drugs and all programs in development for the same indication. Use PubMed, FDA approval databases, and company pipelines. Count how many competitors exist. If there are 10 approved drugs and 15 programs in development for the same indication, the market is crowded. If there are 2 approved drugs and 1 program in development, the market is less crowded.

Next, understand the competitive differentiation. Does the new drug work better than existing options? Does it have fewer side effects? Does it offer a different route of administration (oral instead of injection, for example)? Does it work in a patient population that does not respond to existing drugs? Read the trial data and the company's clinical rationale. If the drug offers a meaningful advantage, it will command higher sales and higher pricing. If it is a "me-too" drug that works similarly to existing options, it will face pricing pressure and lower market share.

Finally, estimate the addressable patient population. Total Addressable Market (TAM) in pharma means every patient who could, in theory, benefit from a drug or product, regardless of whether they will in the end. For a common disease, this is straightforward: count the number of diagnosed patients in major markets. For a rare disease, you may need to search disease registries or published epidemiology. For a new indication, you may need to estimate based on related conditions. The addressable market is the upper bound on peak sales. A drug for a disease with 100,000 patients worldwide cannot generate $10 billion in annual sales, no matter how effective it is.

Calculate risk-adjusted pipeline value

Combine stage, probability, timeline, and market size into a single metric called risk-adjusted net present value (rNPV). This method calculates value based on projected future cash flows, adjusted for the high risks inherent in biotech development. Risk-adjusted NPV applies success probabilities at each clinical and regulatory milestone to model potential outcomes credibly.

The formula is: sc-camel-r-n-p-v = (Peak Sales × Probability of Approval × Years of Patent Life) / (1 + Discount Rate) ^ Years to Market.

Suppose a drug has peak sales of $500 million, a 20 percent probability of approval, 12 years of remaining patent life, and reaches market in 5 years. Use a discount rate of 10 percent, which reflects the company's weighted average cost of capital. The calculation is: ($500 million × 0.20 × 12) / (1.10 ^ 5) = ($1.2 billion) / (1.61) = roughly $745 million in risk-adjusted value.

The revenue curve typically spans 12 to 15 years of commercial life for a drug with standard patent protection. This means that peak sales do not last forever. After patent expiration, generic competition typically erodes sales sharply. The formula above accounts for this by using years of patent life, not total commercial life.

Calculate rNPV for each program in the pipeline. Sum the results to get the total risk-adjusted pipeline value. This number is comparable across companies and across time. A company with a pipeline rNPV of $5 billion has more value in development than a company with $2 billion, holding all else equal. Track this metric over time. If pipeline value is declining, it means the company is not replacing programs that advance or fail with new programs of equivalent value.

Recognize red flags and common pitfalls

Pipeline quality is not always obvious from the headline numbers. A company might report "15 programs in development" and appear strong, but if 12 are in preclinical and only 1 is in Phase 3, the near-term value is low. Learn to spot the warning signs.

Pipeline concentration and stage distribution

A pipeline concentrated in early stages carries higher risk than one distributed across stages. Preclinical and Phase 1 programs have high success rates individually, but only a small fraction of them will ever reach market. Only 1 in 10,000 compounds that start in preclinical research make it to market.

Conversely, a pipeline with multiple Phase 3 programs is closer to revenue and has already passed the highest-failure stages. A single Phase 3 program is worth more in expected value than 10 preclinical programs, even though the preclinical programs outnumber it.

Also watch for pipeline concentration in a single asset. If a company has 10 programs but 8 are in the same indication and 7 are from the same drug class, the pipeline is not as diverse as it appears. If the lead program fails, the entire pipeline may be at risk because the company has placed its bets on a narrow therapeutic approach.

Calculate the percentage of programs at each stage. A healthy pipeline typically has programs distributed across multiple stages. A pipeline with a high proportion in preclinical is speculative. A pipeline with a high proportion in Phase 3 is mature but may face challenges when those programs are approved or fail.

Trial design and patient population concerns

Not all Phase 2 or Phase 3 trials are created equal. A Phase 2 trial with 30 patients in an open-label design is weaker than a Phase 2 trial with 200 patients in a randomized, double-blind, placebo-controlled design. An exploratory trial may not predict Phase 3 success. The latter is a strong signal.

Red flags in trial design include small patient populations, open-label designs without a control arm, single-arm trials (where every patient gets the drug and there is no comparison group), and short follow-up periods. These designs are cheaper and faster, but they do not provide strong evidence of efficacy. A company might use them to generate early data and attract investment, but regulators and later-stage investors will demand more rigorous evidence.

Patient population concerns arise when a trial enrolls only a narrow slice of the intended commercial population. A Phase 2 trial for a cancer drug might enroll only patients with a specific genetic mutation, which makes the trial easier to run but does not prove the drug works in the broader cancer population. A Phase 2 trial for a heart disease drug might enroll only younger patients without comorbidities, which does not predict real-world success in older, sicker patients. Check the trial inclusion and exclusion criteria on ClinicalTrials.gov. If the trial population is much narrower than the commercial population the company plans to target, adjust your success estimate downward.

Another concern is trial endpoints. A Phase 2 trial might use a surrogate endpoint (a biomarker that is believed to predict clinical benefit but is not itself a clinical benefit) instead of a clinical endpoint (an outcome that directly affects patient health). A trial showing that a drug lowers cholesterol is not the same as a trial showing that it reduces heart attacks. Regulators may require clinical endpoints in Phase 3, so a Phase 2 program based on surrogate endpoints may face a higher bar in Phase 3.

Do this automatically

Manually compiling pipeline data from SEC filings and clinical trial registries, classifying dozens of programs by stage and indication, and calculating success probabilities for each candidate requires hours of research and spreadsheet work repeated quarterly as pipelines evolve. Software can systematize this collection, categorization, and probability calculation to produce an updated pipeline assessment in minutes rather than days. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.